FIRST LOOK: Harnessing Endogenous Mechanisms of Programmed Gene Expression for Therapeutic Benefit in Cardiometabolic Disorders


Proximal mechanisms for programmatic control of gene expression exist that underlie the complex, distinct and at times disparate components of cardiometabolic health and dysfunction. Identifying such pathways offers new insights into physiologic and pathologic states, novel treatment strategies and a more rational basis for therapies based on endogenous biology. Through this focus, we identified how modulating key nuclear receptors limits inflammation or decreases visceral obesity, under pursuit as novel therapies.

Epigenetics offers a completely distinct way to control complex transcriptional programs via histone modifications. While most efforts have focused on the placing (‘writers’, e.g. HATs) or removal (‘erasers’, e.g. HDACs) of histone marks, less attention has been directed to epigenetic proteins that bind to these marks (‘readers’) and allow transcription to proceed. The bromodomain and extra-terminal (BET)-containing family, including BRD2, BRD3 and BRD4, which bind to acetylated histones, are epigenetic reader proteins strongly implicated as therapeutic targets in cancer but previously unexplored in cardiovascular and metabolic disorders. In endothelial cells (ECs), we found BRD4 to be essential in transducing the inflammatory NF-kappa B signal to chromatin. In response to TNFα, endothelial BRD4 undergoes massive redeployment to a defined set of de novo super enhancers that drives the resulting pro-inflammatory, pro-atherosclerotic program, as seen in global ChIP-Seq studies. In vivo, BET inhibition decreases inflammation and atherosclerosis.

Of note, TNFα stimulation decommissions BRD4 already active in running an endothelial gene expression program under basal conditions. BET modulation offers several novel therapeutic approaches. Selective BET inhibition, via distinct chemical structures and drug delivery, allows for potent disruption of a coordinated program involved in the pathogenesis of specific diseases while BET biology provides unique targets for manipulation. Separately, BET localization across the genome provides a new way of identifying previously unrecognized players in the inflammation and atherosclerosis as well as the maintenance of normal endothelial function. Such efforts are further supported by additional work extending BET action to other vascular and metabolic settings.


For more information about Dr. Plutzky’s research, please contact Partners HealthCare Innovation by clicking here.

Most Recent Posts:

Blog CILP 2023 Cohort image

Meet the 2023 Commercialization and Inclusive Leadership Program Participants

Congratulations to all the participants chosen to attend the 2023 Mass General Brigham Commercialization and Inclusive Leadership…

Read More
Blog 2023 WMIF image

Connect with global leaders in healthcare innovation at the 2023 World Medical Innovation Forum June 12-14

The annual World Medical Innovation Forum is being held in person at the Westin Seaport District in…

Read More
Blog Employee Service Recognition image

Innovation Employees Celebrate Years of Service Milestones

More than 500 Mass General Brigham employees were honored in the recent 26th annual Enterprise Services Employee…

Read More